Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06176508
PHASE2

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Sponsor: Hansoh BioMedical R&D Company

View on ClinicalTrials.gov

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Official title: A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2024-02-26

Completion Date

2026-08-28

Last Updated

2024-07-18

Healthy Volunteers

No

Interventions

DRUG

HS-10374

Administered orally QD for 16 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 16 weeks

DRUG

Tofacitinib 5Mg Tab,Oral

Administered orally BID for 16 weeks

Locations (1)

Huashan Hospital affiliated to Fudan University

Shanghai, Shanghai Municipality, China